AI Terminal
Vivoryon Therapeutics N.V.
Report Publication Announcement • Nov 3, 2025
3896_rns_2025-11-03_e4e5743b-d700-4e8b-82a0-6b6b77769a0d.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
Halle (Saale) / Munich, Germany, November 3, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company's management will participate in the following medical and investor conferences in November:
American Society of Nephrology (ASN) Kidney Week 2025
Date: November 5 – 9, 2025 Location: Houston, TX, USA
Title: "Correlation of eGFR and pE-CCL2 in Older Adult Patients Treated with Varoglutamstat: Data
from VIVIAD, a Phase 2B Randomized Clinical Trial"
Presentation Time: Thursday, November 6, 10:00 am – 12:00 pm CST / 5:00 pm - 7:00 pm CET
Session: Late-Breaking Research Posters Abstract number/poster details: TH-PO1206
Attendees: Michael Schaeffer, PhD, CBO; Julia Neugebauer, PhD, COO
Link to conference: American Society of Nephrology | Kidney Week - Annual Meeting (2025)
1x1 meetings around the Jefferies Global Healthcare Conference
Date: November 18 – 20, 2025
Location: London, UK
Attendees: Frank Weber, MD, CEO; Julia Neugebauer, PhD, COO
To meet the team contact: [email protected]
Deutsches Eigenkapitalforum
Date: November 24 – 26, 2025 Location: Frankfurt/M, Germany
Attendee: Julia Neugebauer, PhD, COO
Link to conference: Deutsches Eigenkapitalforum
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of Vivoryon Therapeutics N.V. (the "Company"), estimates and projections with respect to the market for the Company's products and forecasts and statements as to when the Company's products may be available. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management's current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. The Company's results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company's future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contact Vivoryon Therapeutics N.V. Dr. Manuela Bader, Director IR & Communication
Email: [email protected]
LifeSci Advisors
Sandya von der Weid Tel: +41 78 680 05 38
Email: [email protected]
Media Contact Trophic Communications Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: [email protected]